New-Onset Psoriatic Arthritis under Biologics in Psoriasis Patients: An Increasing Challenge?

Psoriasis and psoriatic arthritis (PsA) development is sustained by tumor necrosis factor (TNF)α, interleukin (IL)17, and IL23; hence, biologics targeting those cytokines represent useful therapeutic weapons for both conditions. Nevertheless, biologics strongly reduce PsA risk; several studies repor...

Descripción completa

Detalles Bibliográficos
Autores principales: Megna, Matteo, Ocampo-Garza, Sonia Sofia, Potestio, Luca, Fontanella, Giuseppina, Gallo, Lucia, Cacciapuoti, Sara, Ruggiero, Angelo, Fabbrocini, Gabriella
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8533054/
https://www.ncbi.nlm.nih.gov/pubmed/34680599
http://dx.doi.org/10.3390/biomedicines9101482

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8533054/
https://www.ncbi.nlm.nih.gov/pubmed/34680599
http://dx.doi.org/10.3390/biomedicines9101482

Ejemplares similares